Your browser doesn't support javascript.
loading
The Tam formula: A pilot study for a new treatment for melasma.
Srivastava, Radhika; John, Ann M; Tam, Alison; Firoz, Bahar F.
Afiliação
  • Srivastava R; Department of Dermatology, Rutgers Robert Wood Johnson Medical School at 1 World's Fair Drive Somerset, NJ, USA.
  • John AM; Department of Dermatology, Rutgers Robert Wood Johnson Medical School at 1 World's Fair Drive Somerset, NJ, USA.
  • Tam A; Plastic Surgery Vegas, Las Vegas, Nevada, USA.
  • Firoz BF; Department of Dermatology, Rutgers Robert Wood Johnson Medical School at 1 World's Fair Drive Somerset, NJ, USA.
J Cosmet Dermatol ; 20(7): 2168-2171, 2021 Jul.
Article em En | MEDLINE | ID: mdl-33206439
BACKGROUND: Melasma is a common hyperpigmentation disorder with numerous, but often unsatisfactory treatment options. AIMS: A pilot study to evaluate the efficacy and safety of a novel topical combination of 12% hydroquinone, 6% kojic acid, and 5% vitamin C cream for melasma. PATIENTS AND METHODS: A pilot study of 6 women with melasma was conducted at an academic dermatology department and a private dermatology practice to evaluate the efficacy of a topical combination of 12% hydroquinone, 6% kojic acid, and 5% vitamin C cream, entitled the "Tam Formula." Two blinded evaluators calculated Melasma Area and Severity Index (MASI) Scores before and after treatment to evaluate change from baseline, and statistical analysis was performed. RESULTS: Treatment with this combination topical cream resulted in an average 63.77 ± 22.10 percent reduction in MASI scores. CONCLUSIONS: While there is a need for further investigation, this pilot study indicates the Tam Formula may provide an alternative treatment option for melasma.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Melanose Limite: Female / Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Melanose Limite: Female / Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article